RudaCure también actively pursuing mercado global entry. La empresa establecido an overseas subsidiaria in 2021 and participates in major pharmaceutical/bio exhibition partnering events such as JPM, Bio-Europe, and Bio-USA to attract overseas inversión and transferencia de tecnologías. La empresa también engaged with overseas accelerators including KIC (Korea Innovación Center), the U.S. Mass Challenge programa, and the Shinhan Square Bridge Global Program, as well as U.S. bio events including UKC2022 and the RESI Conference. Most recently, la empresa won premios at IR competitions at UKC2022 (Washington D.C.) and RESI Conference (Boston).
Regarding future plans, El CEO Kim declaró: "We will advance RCI001 nacional Phase 1 ensayo clínicos within este año," adding, "Our goal is to proceed with U.S. FDA Phase 2 ensayo clínicos by the primer semestre of 2023."
Founded: July 2018
Main business: New desarrollo de fármacos including enfermedad de ojo seco and tratamiento del dolor crónicos
Achievements: Certified corporate I+D center (2019.1), Certified venture company (2019.5), Technology-innovador SME certificación (2022.3), Ministry of Employment and Labor Strong Small Enterprise designación (2022.05). RCI001 ojo seco tratamiento: 1 solicitud de patente + 2 patents registró; RCI002 tratamiento del dolor crónico: 5 solicitud de patentes + 1 patent registró; 2 desarrollo conjunto patents registró; 2 trademark registrations; KRW 15 billion joint I+D acuerdo with Hanlim Pharmaceutical; KRW 6 billion Serie A inversión completó (2022.5); RudaCure U.S.A. incorporated (2021.08); Expanded to dual Songdo HQ and Seoul branch structure (2022.07); 2022 Korean-American Scientists Conference SBA Premio; RESI Conference pitch competition premio winner
📊 Related Materials & Evidence
[Patent certificate image slot]Patent Registration Certificate (RCI001)
[Event photo image slot]RESI Conference on-site
🔗 Related Links: